SENS-AI
REM Results Bearish

REMGRO LIMITED - Summary of Mediclinic Holdings Limited results for the year ended 31 March 2026

Remgro Limited
Full analysis

What this filing means

Remgro's voluntary disclosure of Mediclinic's FY26 results reveals a $733m net loss driven by massive Swiss impairments, overshadowing a 45% increase in adjusted operating earnings.

Remgro released the financial results for its hospital business, Mediclinic. While the hospitals made more money from daily operations, the company had to wipe over $1.2 billion off the official value of its Swiss assets, leading to a large overall loss on paper.

Bull case

  • Adjusted EBITDA grew by 14% to $842m, with the EBITDA margin expanding to 15.7% supported by revenue growth and cost efficiencies.
  • Balance sheet discipline improved, with the leverage ratio reducing to 2.7x from 3.1x and cash conversion strengthening to 106%.

Bear case

  • Headline growth was significantly flattered by currency translation, as adjusted revenue growth of 11% drops to only 5% in constant currency terms.
  • The restructuring of MCSA and Hirslanden into disposal groups held for sale compromises historical comparability and introduces complexity in assessing ongoing value.

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

Remgro voluntarily published Mediclinic's FY26 financial summary, disclosing a $733m net loss driven by $1.244bn in Swiss and restructuring-related impairments, alongside a 45% rise in adjusted earnings to $345m. The divergence highlights that while underlying operational cash conversion and margins improved, significant value destruction occurred in the Swiss division ahead of the planned MCSA and Hirslanden ownership split. This update provides Mediclinic's unreviewed standalone figures only and does not establish Remgro's consolidated group financials or dividend expectations. Investor Takeaway: The strong operational performance of the underlying assets is heavily overshadowed by the $1.244bn impairment hit, making it a mixed update that leaves the broader restructuring thesis intact but rebased.

The unreviewed Mediclinic figures highlight strong underlying cash generation but reveal massive write-downs in the Swiss division ahead of the planned split. No immediate portfolio action required for Remgro holders.

Decision framework

Current stance: Filing Negative

Key drivers

  • Adjusted EBITDA grew by 14% to $842m, with the EBITDA margin expanding to 15.7% supported by revenue growth and cost efficiencies.
  • Balance sheet discipline improved, with the leverage ratio reducing to 2.7x from 3.1x and cash conversion strengthening to 106%.

Key risks

  • Headline growth was significantly flattered by currency translation, as adjusted revenue growth of 11% drops to only 5% in constant currency terms.
  • The restructuring of MCSA and Hirslanden into disposal groups held for sale compromises historical comparability and introduces complexity in assessing ongoing value.

What would change the view

  • Management provides credible upward guidance with measurable support.
  • Margin/cash-flow quality improves in the next reporting cycle.
  • Risk factors in this filing are explicitly resolved by subsequent disclosures.

Evidence from the filing

  • Adjusted EBITDA grew by 14% to $842m, with the EBITDA margin expanding to 15.7% supported by revenue growth and cost efficiencies.

    “Adjusted EBITDA increased by 14% to $842m (FY25: $737m) and 8% in constant currency terms. The Group's adjusted EBITDA margin was 15.7% (FY25: 15.3%), supported by a combination of revenue growth and cost efficiencies.”

  • Balance sheet discipline improved, with the leverage ratio reducing to 2.7x from 3.1x and cash conversion strengthening to 106%.

    “Leverage ratio reduced to 2.7x (FY25: 3.1x)”

  • Headline growth was significantly flattered by currency translation, as adjusted revenue growth of 11% drops to only 5% in constant currency terms.

    “Adjusted revenue increased by 11% to $5 356m (FY25: $4 818m), up 5% in constant currency terms. ... Adjusted EBITDA increased by 14% to $842m (FY25: $737m) and 8% in constant currency terms.”

  • The restructuring of MCSA and Hirslanden into disposal groups held for sale compromises historical comparability and introduces complexity in assessing ongoing value.

    “As a result, the MCSA and Hirslanden divisions have been classified as disposal groups held for sale and presented as discontinued operations in terms of IFRS 5.”
Category
Results
Event posture
No Edge
Published
May 29, 2026

More on Remgro Limited

Remgro Limited (REM) share price All Remgro Limited SENS announcements

Related filings